Skip to main
TEVA
TEVA logo

Teva Pharmaceutical (TEVA) Stock Forecast & Price Target

Teva Pharmaceutical (TEVA) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Teva Pharmaceutical Industries has demonstrated a robust performance in its generics segment, which is expected to generate $9.5 billion in global sales for 2024, representing 57% of the company's total revenue, an increase from 55% in 2023. The company has also achieved notable geographic expansion, with non-US sales growing by 5.3% year-over-year in 2024, highlighting a strong international market presence and the ongoing rollout of products like Ajovy and Austedo in multiple countries. Additionally, European sales accounted for 31% of revenues, and international sales rose from 13% in 2022 to 15%, indicating a positive trajectory for overall sales diversification.

Bears say

Teva Pharmaceutical Industries has experienced significant challenges, as indicated by a substantial decline in US sales for affected products, which represented only 4% of the company's total US sales in 2024, reflecting a troubling trend since 2020. Additionally, the company's active pharmaceutical ingredient (API) segment reported a notable 16% decline in third-party sales in 2023, despite an overall 6% increase in total sales, highlighting issues related to generic oversupply and margin erosion. These factors contributed to a 13% year-over-year decline in US generic sales for the quarter, underscoring a concerning outlook for Teva's core business performance.

Teva Pharmaceutical (TEVA) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Teva Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Teva Pharmaceutical (TEVA) Forecast

Analysts have given Teva Pharmaceutical (TEVA) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Teva Pharmaceutical (TEVA) has a Strong Buy consensus rating as of Nov 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Teva Pharmaceutical (TEVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.